Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2007 Nov 13;13(4):444–464. doi: 10.1111/j.1527-3458.2007.00024.x

The Preclinical Properties of a Novel Group II Metabotropic Glutamate Receptor Agonist LY379268

Gabor Imre 1
PMCID: PMC6494167  PMID: 18078428

ABSTRACT

Activation of group II metabotropic glutamate (mGlu2/3) receptors reduces excessive glutamate release that is often associated with neurodegenerative and psychiatric disorders. This finding encouraged the search for potent and selective agonists as potential therapeutic agents. The search led to the discovery of LY379268 {(‐)‐2‐oxa‐4‐aminobicyclo[3.1.0]hexane‐4,6‐dicarboxylic acid}, which is a highly potent and systemically available mGlu2/3 receptor agonist. LY379268 was effective in several animal models of stroke, epilepsy, drug abuse, schizophrenia, and pain. Suppression of motor activity is the major side effect of LY379268. Upon repeated administration tolerance develops to this side effect, while the therapeutic effects of LY379268 remain. To date, no clinical data with LY379268 are available. This review article summarizes the preclinical pharmacology of LY379268.

Keywords: Analgesics, Antipsychotics, Anxiolytics, Drug abuse, Glutamate, LY379268, mGlu 2/3 receptors, Neuroprotection

Full Text

The Full Text of this article is available as a PDF (148.7 KB).

REFERENCES

  1. Aghajanian GK, Marek GJ (1999) Serotonin, via 5‐HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161‐171. [DOI] [PubMed] [Google Scholar]
  2. Anwyl R (1999) Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Res Rev 29:83‐120. [DOI] [PubMed] [Google Scholar]
  3. Bäckström P, Hyytiä P (2005) Suppression of alcohol self‐administration and cue‐induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)‐3,4‐DCPG. Eur J Pharmacol 528:110‐118. [DOI] [PubMed] [Google Scholar]
  4. Baptista MA, Martin‐Fardon R, Weiss F (2004) Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: Comparison between cocaine and a potent conventional reinforcer. J Neurosci 24:4723‐4727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barton ME, Peters SC, Shannon HE (2003) Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 56:17‐26. [DOI] [PubMed] [Google Scholar]
  6. Battaglia G, Fornai F, Busceti CL, Aloisi G, Cerrito F, De Blasi A, Melchiorri D, Nicoletti F (2002) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci 22:2135‐2141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Battaglia G, Busceti CL, Pontarelli F, Biagioni F, Fornai F, Paparelli A, Bruno V, Ruggieri S, Nicoletti F (2003) Protective role of group‐II metabotropic glutamate receptors against nigro‐striatal degeneration induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in mice. Neuropharmacology 45:155‐166. [DOI] [PubMed] [Google Scholar]
  8. Behrens MM, Strasser U, Heidinger V, Lobner D, Yu SP, McDonald JW, Won M, Choi DW (1999) Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity. Neuropharmacology 38:1621‐1630. [DOI] [PubMed] [Google Scholar]
  9. Bond A, Ragumoorthy N, Monn JA, Hicks CA, Ward MA, Lodge D, O'Neill MJ (1999) LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci Lett 273:191‐194. [DOI] [PubMed] [Google Scholar]
  10. Bond A, Jones NM, Hicks CA, Whiffin GM, Ward MA, O'Neill MF, Kingston AE, Monn JA, Ornstein PL, Schoepp DD, et al (2000) Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: Investigations into possible mechanism of action in vivo. J Pharmacol Exp Ther 294:800‐809. [PubMed] [Google Scholar]
  11. Bossert JM, Liu SY, Lu L, Shaham Y (2004) A role of ventral tegmental area glutamate in contextual cue‐induced relapse to heroin seeking. J Neurosci 24:10726‐10730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bossert JM, Busch RF, Gray SM (2005) The novel mGluR2/3 agonist LY379268 attenuates cue‐induced reinstatement of heroin seeking. Neuroreport 16:1013‐1016. [DOI] [PubMed] [Google Scholar]
  13. Bossert JM, Poles GC, Sheffler‐Collins SI, Ghitza UE (2006a) The mGluR2/3 agonist LY379268 attenuates context‐ and discrete cue‐induced reinstatement of sucrose seeking but not sucrose self‐administration in rats. Behav Brain Res 173:148‐152. [DOI] [PubMed] [Google Scholar]
  14. Bossert JM, Gray SM, Lu L, Shaham Y (2006b) Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context‐induced relapse to heroin seeking. Neuropsychopharmacology 31:2197‐2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor‐beta. J Neurosci 18:9594‐9600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, Knöpfel T, Kuhn R, Nicoletti F (1997) The neuroprotective activity of group‐II metabotropic glutamate receptors requires new protein synthesis and involves a glial‐neuronal signaling. J Neurosci 17:1891‐1897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cai Z, Xiao F, Fratkin JD, Rhodes PG (1999) Protection of neonatal rat brain from hypoxic‐ischemic injury by LY379268, a group II metabotropic glutamate receptor agonist. Neuroreport 10:3927‐3931. [DOI] [PubMed] [Google Scholar]
  18. Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, Sallee FR, Sharp JW, Sharp FR (2004) The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK‐801: Possible implications for psychosis. Neuropharmacology 47:1135‐1145. [DOI] [PubMed] [Google Scholar]
  19. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889‐907. [DOI] [PubMed] [Google Scholar]
  20. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d‐amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161‐170. [PubMed] [Google Scholar]
  21. Cartmell J, Monn JA, Schoepp DD (2000a) Attenuation of specific PCP‐evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 48:423‐429. [DOI] [PubMed] [Google Scholar]
  22. Cartmell J, Monn JA, Schoepp DD (2000b) Tolerance to the motor impairment, but not to the reversal of PCP‐induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedeberg's Arch Pharmacol 361:39‐46. [DOI] [PubMed] [Google Scholar]
  23. Cartmell J, Monn JA, Schoepp DD (2000c) The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400: 221‐224. [DOI] [PubMed] [Google Scholar]
  24. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD (2000d) The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4‐dihydroxyphenylacetic acid, homovanillic acid, and 5‐hydroxyindole‐3‐acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem 75:1147‐1154. [DOI] [PubMed] [Google Scholar]
  25. Cartmell J, Salhoff CR, Perry KW, Monn JA, Schoepp DD (2000e) Dopamine and 5‐HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Res 887:378‐384. [DOI] [PubMed] [Google Scholar]
  26. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847‐855. [DOI] [PubMed] [Google Scholar]
  27. Chartoff EH, Heusner CL, Palmiter RD (2005) Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 30:1324‐1333. [DOI] [PubMed] [Google Scholar]
  28. Chen YL, Huang CC, Hsu KS (2001) Time‐dependent reversal of long‐term potentiation by low frequency stimulation at the hippocampal mossy fiber‐CA3 synapses. J Neurosci 21:3705‐3714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Clark M, Johnson BG, Wright RA, Monn JA, Schoepp DD (2002) Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine‐sensitized rats. Pharmacol Biochem Behav 73:339‐346. [DOI] [PubMed] [Google Scholar]
  30. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205‐237. [DOI] [PubMed] [Google Scholar]
  31. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1‐105. [DOI] [PubMed] [Google Scholar]
  32. D'Onofrio M, Cuomo L, Battaglia G, Ngomba RT, Storto M, Kingston AE, Orzi F, De Blasi A, Di Iorio P, Nicoletti F, et al (2001) Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways. J Neurochem 78:435‐445. [DOI] [PubMed] [Google Scholar]
  33. Eng DL, Lee YL, Lal PG (1997) Expression of glutamate uptake transporters after dibutyryl cyclic AMP differentiation and traumatic injury in cultured astrocytes. Brain Res 778:215‐221. [DOI] [PubMed] [Google Scholar]
  34. Fisher K, Coderre TJ (1996) The contribution of metabotropic glutamate receptors (mGluRs) to formalin‐induced nociception. Pain 68:255‐263. [DOI] [PubMed] [Google Scholar]
  35. Fundytus ME (2001) Glutamate receptors and nociception. Implications for the drug treatment of pain. CNS Drugs 15:29‐58. [DOI] [PubMed] [Google Scholar]
  36. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptor has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181‐1187. [DOI] [PubMed] [Google Scholar]
  37. Greenslade RG, Mitchell SN (2004) Selective action of (–)‐2‐oxa‐4‐aminobicyclo[3.1.0]hexane‐4, 6‐dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine‐induced dopamine release in the nucleus accumbens shell. Neuropharmacology 47:1‐8. [DOI] [PubMed] [Google Scholar]
  38. Hotsenpiller G, Giorgetti M, Wolf ME (2001) Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. Eur J Neurosci 14:1843‐1855. [DOI] [PubMed] [Google Scholar]
  39. Huang LQ, Rowan MJ, Anwyl R (1997) mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro. Neuroreport 8:687‐693. [DOI] [PubMed] [Google Scholar]
  40. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ (2006) Effects of the mGluR2/3 agonist LY379268 on ketamine evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84:392‐399. [DOI] [PubMed] [Google Scholar]
  41. Jackson A, Mead AN, Rocha BA, Stephens DN (1998) AMPA receptors and motivation for drug: Effect of the selective antagonist NBQX on behavioural sensitization and on self‐administration in mice. Behav Pharmacol 9:457‐467. [DOI] [PubMed] [Google Scholar]
  42. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201‐225. [DOI] [PubMed] [Google Scholar]
  43. Johnson MP, Chamberlain M. (2002) Modulation of stress‐induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43:799‐808. [DOI] [PubMed] [Google Scholar]
  44. Johnson MP, Kelly G, Chamberlain M (2001) Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. J Neuroendocrinol 13:670‐677. [DOI] [PubMed] [Google Scholar]
  45. Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HA (2005) Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49:206‐218. [DOI] [PubMed] [Google Scholar]
  46. Kew JN, Ducarre JM, Pflimlin MC, Mutel V, Kemp JA (2001) Activity‐dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1. Neuropharmacology 40:20‐27. [DOI] [PubMed] [Google Scholar]
  47. Kim JH, Vezina P (2002) The mGlu2/3 receptor agonist LY379268 blocks the expression of locomotor sensitization by amphetamine. Pharmacol Biochem Behav 73:333‐337. [DOI] [PubMed] [Google Scholar]
  48. Kim JH, Austin JD, Tanabe L, Creekmore E, Vezina P (2005) Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine. Eur J Neurosci 21:295‐300. [DOI] [PubMed] [Google Scholar]
  49. Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD (1999a) Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol 377:155‐165. [DOI] [PubMed] [Google Scholar]
  50. Kingston AE, O'Neill MJ, Bond A, Bruno V, Battaglia G, Nicoletti F, Harris JR, Clark BP, Monn JA, Lodge D, et al (1999b) Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Ann N Y Acad Sci 890:438‐449. [DOI] [PubMed] [Google Scholar]
  51. Kłodzinska A, Bijak M, Tokarski K, Pilc A (2002) Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behavior 73:327‐332. [DOI] [PubMed] [Google Scholar]
  52. Kotlinska J, Biala G (2000) Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol J Pharmacol 52:179‐185. [PubMed] [Google Scholar]
  53. Lam AG, Soriano MA, Monn JA, Schoepp DD, Lodge D, McCulloch J (1998) Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neurosci Lett 254:121‐123. [DOI] [PubMed] [Google Scholar]
  54. Lam AGM, Monn JA, Schoepp DD, Lodge D, McCulloch J (1999) Group II selective metabotropic glutamate receptor agonists and local cerebral glucose use in the rat. J Cereb Blood Flow Metab 19:1083‐1091. [DOI] [PubMed] [Google Scholar]
  55. Laurie DJ, Schoeffter P, Wiederhold KH, Sommer B (1997) Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology 36:145‐152. [DOI] [PubMed] [Google Scholar]
  56. Liu XB, Munoz A, Jones EG (1998) Changes in subcellular localization of metabotropic glutamate receptor subtypes during postnatal development of mouse thalamus. J Comp Neurol 395:450‐465. [DOI] [PubMed] [Google Scholar]
  57. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003a) Effects of ketamine and N‐methyl‐D‐aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697‐706. [DOI] [PubMed] [Google Scholar]
  58. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, et al (2003b) Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622‐1632. [DOI] [PubMed] [Google Scholar]
  59. Lorrain DS, Baccei CS, Correa LD, Bristow LJ (2005) Comparison of the effects of diazepam, the CRF1 antagonist CP‐154,526 and the group II mGlu receptor agonist LY379268 on stress‐evoked extracellular norepinephrine levels. Neuropharmacology 48:927‐935. [DOI] [PubMed] [Google Scholar]
  60. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5 hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76‐87. [PubMed] [Google Scholar]
  61. Marino MJ, Conn PJ (2002) Direct and indirect modulation of the N‐methyl D‐aspartate receptor: Potential for the development of novel antipsychotic therapies. Current Drug Targets 1:1‐16. [DOI] [PubMed] [Google Scholar]
  62. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A, Scaccianoce S, Riozzi B, Melchiorri D, Nicoletti F (2002) Imipramine treatment up‐regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42:1008‐1015. [DOI] [PubMed] [Google Scholar]
  63. Matrisciano F, Scaccianoce S, Del Bianco P, Panaccione I, Canudas AM, Battaglia G, Riozzi B, Ngomba RT, Molinaro G, Tatarelli R, et al (2005) Metabotropic glutamate receptors and neuroadaptation to antidepressants: Imipramine‐induced down‐regulation of β‐adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J Neurochem 93:1345‐1352. [DOI] [PubMed] [Google Scholar]
  64. Mineff E, Valtschanoff J (1999) Metabotropic glutamate receptors 2 and 3 expressed by astrocytes in rat ventrobasal thalamus. Neurosci Lett 270:95‐98. [DOI] [PubMed] [Google Scholar]
  65. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349‐1352. [DOI] [PubMed] [Google Scholar]
  66. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921‐2927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Moldrich RX, Jerey M, Talebi A, Beart PM, Chapman AG, Meldrum BS (2001) Antiepileptic activity of group II metabotropic glutamate receptor agonists (‐)‐2‐oxa‐4‐aminobicyclo[3.1.0]hexane‐4,6‐dicarboxylate (LY379268) and (‐)‐2‐thia‐4‐aminobicyclo[3.1.0]‐hexane‐4,6‐dicarboxylate (LY389795). Neuropharmacology 41:8‐18. [DOI] [PubMed] [Google Scholar]
  68. Moldrich RX, Aprico K, Diwakarla S, O'Shea RD, Beart PM (2002) Astrocyte mGlu2/3‐mediated cAMP potentiation is calcium sensitive: Studies in murine neuronal and astrocyte cultures. Neuropharmacology 43:189‐203. [DOI] [PubMed] [Google Scholar]
  69. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, et al (1997) Design, synthesis, and pharmacological characterization of (+)‐2 aminobicyclo [3.1.0] hexane‐2,6‐dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528‐537. [DOI] [PubMed] [Google Scholar]
  70. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright RA, Johnson BG, et al (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)‐2‐aminobicyclo[3.1.0]hexane‐2,6‐dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42:1027‐1040. [DOI] [PubMed] [Google Scholar]
  71. Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osborne DJ, Duty S, O'Neill MJ (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73:455‐466. [DOI] [PubMed] [Google Scholar]
  72. Neugebauer V, Chen PS, Willis WD (2000) Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate STT cells. J Neurophysiol 84:2998‐3009. [DOI] [PubMed] [Google Scholar]
  73. Ngomba RT, Biagioni F, Casciato S, Willems‐van Bree E, Battaglia G, Bruno V, Nicoletti F, Van Luijtelaar ELJM (2005) The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike‐wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology 49:89‐103. [DOI] [PubMed] [Google Scholar]
  74. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009‐1018. [DOI] [PubMed] [Google Scholar]
  75. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. J Comp Neurol 335:252‐266. [DOI] [PubMed] [Google Scholar]
  76. Ohishi H, Neki A, Mizuno N (1998) Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: An immunohistochemical study with a monoclonal antibody. Neurosci Res 30:65‐82. [DOI] [PubMed] [Google Scholar]
  77. Peters J, Kalivas PW (2006) The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine‐ and food‐seeking behavior in rats. Psychopharmacology 186:143‐149. [DOI] [PubMed] [Google Scholar]
  78. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ (1996) The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71:949‐976. [DOI] [PubMed] [Google Scholar]
  79. Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P (2002) Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125:2635‐2645. [DOI] [PubMed] [Google Scholar]
  80. Poli A, Beraudi A, Villani L, Storto M, Battaglia G, Di Giorgi Gerevini V, Cappuccio I, Caricasole A, D'Onofrio M, Nicoletti F (2003) Group II metabotropic glutamate receptors regulate the vulnerability to hypoxic brain damage. J Neurosci 23:6023‐6029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Popik P, Wrobel M, Rygula R, Bisaga A, Bespalov AY (2003) Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. Behav Pharmacol 14:237‐244. [DOI] [PubMed] [Google Scholar]
  82. Riegel AC, Ali SF, French ED (2003) Toluene‐induced locomotor activity is blocked by 6‐hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268. Neuropsychopharmacology 28:1440‐1447. [DOI] [PubMed] [Google Scholar]
  83. Scaccianoce S, Matrisciano F, Del Bianco P, Caricasole A, Gerevini VD, Cappuccio I, Melchiorri D, Battaglia G, Nicoletti F (2003) Endogenous activation of group‐II metabotropic glutamate receptors inhibits the hypothalamic‐pituitary‐adrenocortical axis. Neuropharmacology 44:555‐561. [DOI] [PubMed] [Google Scholar]
  84. Scanziani M, Salin PA, Vogt KE, Malenka RC, Nicoll RA (1997) Use‐dependent increases in glutamate concentration activates presynaptic metabotropic glutamate receptors. Nature 385:630‐634. [DOI] [PubMed] [Google Scholar]
  85. Schiefer J, Sprünken A, Puls C, Lüesse H, Milkereit A, Milkereit E, Johann V, Kosinski CM (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 1019:246‐254. [DOI] [PubMed] [Google Scholar]
  86. Schlag BD, Vondrasek JR, Munir M, Kalandadze A, Zelenaia OA, Rothstein JD, Robinson MB (1998) Regulation of the glial Na+‐dependent glutamate transporters by cyclic AMP analogs and neurons. Mol Pharmacol 53:355‐369. [DOI] [PubMed] [Google Scholar]
  87. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12‐20. [PubMed] [Google Scholar]
  88. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431‐1476. [DOI] [PubMed] [Google Scholar]
  89. Schoepp DD, Cartmell J, Johnson BG, Salhoff CR, Wright RA, Tizzano JP, Monn JA (2001) Excitatory amino acids: Ten years later, manaus 98 In: Biomedical and Health Research, vol. 45 Amsterdam : IOS Press, 207‐216. [Google Scholar]
  90. Schubert P, Ogata T, Ferroni S, McRae A, Nakamura Y, Rudolphi K (1996) Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Mol Chem Neuropathol 28:185‐190. [DOI] [PubMed] [Google Scholar]
  91. Sharpe EF, Kingston AE, Lodge D, Monn JA, Headley PM (2002) Systemic pre‐treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br J Pharmacol 135:1255‐1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ, Neki A, Abe T, Nakanishi S, et al (1997) Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 17:7503‐7522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Simmons RMA, Webster AA, Kalra AB, Iyengar S (2002) Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 73:419‐427. [DOI] [PubMed] [Google Scholar]
  94. Smolders I, Lindekens H, Clinckers R, Meurs A, O'Neill MJ, Lodge D, Ebinger G, Michotte Y (2004) In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands. J Neurochem 88:1068‐1077. [DOI] [PubMed] [Google Scholar]
  95. Swanson CJ, Schoepp DD (2002) The group II metabotropic glutamate receptor agonist (‐)‐2‐oxa‐4‐aminobicyclo[3.1.0.]hexane‐4,6‐dicarboxylate (LY379268) and clozapine reverse phencyclidine‐induced behaviors in monoamine‐depleted rats. J Pharmacol Exp Ther 303:919‐927. [DOI] [PubMed] [Google Scholar]
  96. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257‐277. [DOI] [PubMed] [Google Scholar]
  97. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131‐144. [DOI] [PubMed] [Google Scholar]
  98. Watkins JC (2000) L‐glutamate as a central neurotransmitter: Looking back. Biochem Soc Trans 28(4):297‐309. [PubMed] [Google Scholar]
  99. Winder DG, Conn PJ (1996) Roles of metabotropic glutamate receptors in glial function and glial neuronal communication. J Neurosci Res 46:131‐137. [DOI] [PubMed] [Google Scholar]
  100. Winter JC, Eckler JR, Rabin RA (2004) Serotonergic/glutamatergic interactions: The effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233‐240. [DOI] [PubMed] [Google Scholar]
  101. Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK (2003) Group II metabotropic glutamate receptor modulation of DOI‐induced c‐fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28:45‐52. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES